Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials

• DOI: 10.1111/dom.12632
• Publication Date: 2016-01-08T08:05:14Z
• Authors: J. Ard; A. Cannon; C. E. Lewis; H. Lofton; T. Vang Skjøth; B. Stevenin; X. Pi‐Sunyer
• Keywords: Post-hoc analysis; Subgroup analysis; Post hoc; Weight management

The efficacy and safety of liraglutide 3.0 mg versus placebo, as adjunct to diet exercise, was evaluated in racial subgroups. This post hoc analysis pooled data from five double‐blind randomized, placebo‐controlled trials conducted 5325 adults with either a body mass index ( BMI ) ≥27 kg/m 2 plus ≥1 comorbidity or ≥30 . Statistical interaction tests possible treatment effect differences between subgroups: white (4496, 84.4%), black/African‐American (550, 10.3%), Asian (168, 3.2%) other (111, 2.1%). Effects on weight loss, associated metabolic effects profile were generally consistent across All achieved statistically significant mean loss at end‐of‐treatment placebo: 7.7% 2.3%, 6.3% 1.4%, 2.5%, 7.3% 0.49%. Treatment cardiovascular risk markers showed no dependence race (interaction test p > 0.05). Adverse events similar